Contrive Datum Insights has published "Livestock Vaccine Market Size, Share & Industry Analysis, By Animal type (Poultry, Swine, Cattle (Bovine), Sheep & Goat (Ovine/Caprine), Aquaculture, Other Livestock (Equine & Others)), Vaccine type (Live Attenuated, Inactivated / Killed, Toxoid, Recombinant / Subunit, DNA & Vector-based), Disease/indication (Avian Influenza & Newcastle Disease, Foot-and-Mouth Disease, Bovine Respiratory Disease Complex, Porcine Reproductive & Respiratory Syndrome (PRRS), Other Diseases), Route of administration (Injectable, Spray / Aerosol, Oral, In-ovo), Distribution channel (Veterinary Hospitals & Clinics, Retail & Farm Supply Stores, Online & Direct-to-Farm), and Regional Forecast, 2026-2034". The study sizes the global livestock vaccine market at USD 6.85 billion in 2025 and projects growth from USD 7.3 billion in 2026 to USD 12.48 billion by 2034, a compound annual growth rate of 6.93% across the forecast period.
Livestock vaccines are biological products administered to farm animals, including poultry, swine, cattle, sheep, goats and farmed aquatic species, to prevent or control infectious and parasitic diseases before they spread through a herd or flock. They are formulated as live attenuated, inactivated, toxoid, subunit or vector-based products and delivered by injection, oral dosing, spray or in-ovo application depending on the species and disease targeted. Buyers span integrated poultry and swine producers, individual cattle and small ruminant farmers, aquaculture operators, veterinary practices and government animal health agencies running compulsory disease-control programs.
Rising global protein demand expanding herd and flock size
Rising global protein demand expanding herd and flock size is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 6.93% a year, the animal type lines exposed to it move fastest: Aquaculture compounds at 11.06%, taking its share of revenue from 7.01% to 10.02% and its value from USD 0.48 billion to USD 1.25 billion.
The study also runs a bull case: bull assumes faster adoption of recombinant and vector-based vaccine platforms, sustained outbreak-driven mass immunization campaigns, and accelerated public and private investment in vaccination infrastructure across emerging livestock-producing regions. That path ends 2034 at USD 13.48 billion, above the USD 12.48 billion base case.
Against that, bear assumes slower herd and flock expansion, constrained public budgets for compulsory vaccination programs, and delayed adoption of newer vaccine platforms among smallholder and subsistence livestock operations. On that reading 2034 revenue stops at USD 11.48 billion. The weight of the problem sits in Poultry: 34.01% of 2025 revenue growing at 6.6%, well under the market's 6.93%.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Vaccine type | Live Attenuated | 37.96% · USD 2.6 billion | DNA & Vector-based 11.81% |
| Disease/indication | Avian Influenza & Newcastle Disease | 30.03% · USD 2.06 billion | Porcine Reproductive & Respiratory Syndrome (PRRS) 7.66% |
| Route of administration | Injectable | 57.96% · USD 3.97 billion | In-ovo 11.79% |
| Distribution channel | Veterinary Hospitals & Clinics | 51.97% · USD 3.56 billion | Online & Direct-to-Farm 11.87% |
- Regionally, the lead sits with Asia Pacific: 32% of 2025 global revenue, USD 2.19 billion rising to USD 4.37 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 32% in 2025 to 35% in 2034, with revenue growing from USD 2.19 billion to USD 4.37 billion.
- Middle East and Africa remains the smallest region throughout, at 7% of 2025 revenue and 8% by 2034.
- Poultry was the leading animal type line in 2025, taking 34.01% of revenue at USD 2.33 billion.
- Aquaculture is projected to grow at 11.06% over the forecast period, the fastest of any animal type line.
- The United States is the largest single country market at USD 1.39 billion in 2025, 20.29% of global revenue.
The report segments the market across five axes; by animal type, and by vaccine type, disease/indication, route of administration and distribution channel; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 11.48 billion and USD 13.48 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.